AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now

By Rae Ann Varona · July 12, 2024, 10:57 PM EDT

A Connecticut federal judge has tossed a proposed securities fraud class action against BioXcel Therapeutics Inc., saying that while shareholders sufficiently alleged the AI-driven drugmaker made misleading statements concerning a dementia...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Hills et al v. BioXcel Therapeutics, Inc. et al

Case Number

Court

Connecticut

Nature of Suit

Securities/Commodities

Date Filed

July 07, 2023

Recent Articles By Rae

October 30, 2024
5th Circ. Keeps Most No Surprises Act Provisions Intact
October 08, 2024
Elanco Misled Investors About Dog Medicine Safety, Suit Says
October 04, 2024
DOJ Charges Execs, Sales Reps Over Texas 'Pill Mills' Sales
September 30, 2024
Calif. Sues Eureka Hospital For Denying Emergency Abortion
September 23, 2024
'Dreamers' Want In On GOP States' Suit Over ACA Coverage
September 04, 2024
Leech Tishman Combines With Calif. Firm Nelson Hardiman
August 16, 2024
Humana To Pay $90M To End 8-Year Medicare Drug FCA Battle
August 14, 2024
ICE Faces Trimmed Suit Over Detainee's COVID-19 Death
August 08, 2024
4th Circ. Upholds Asylum Denial Over Forced Hospitalizations
July 09, 2024
Pharma Co. Fined $16.9M For Fake Scripts, Ex-VP Arrested